Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Insipidus, Neurohypophyseal Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neurobiological Bases of Paternal Nurturance

NCT02223429
View directory record Official record
Conditions
Healthy
Interventions
Oxytocin, Vasopressin, Placebo
Drug
Lead sponsor
James K. Rilling, PhD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

INDIGO-2: The Effect of High Water Intake on Glucose Regulation in Low-drinkers

NCT04076995
View directory record Official record
Conditions
Dehydration, Diabetes Mellitus, Type 2
Interventions
Water Intake
Other
Lead sponsor
Arizona State University
Other
Eligibility
30 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 2, 2026, 4:11 AM EDT
Withdrawn No phase listed Observational

Serum Vasopressin Levels and Severe Hemorrhagic Shock

NCT01676454
View directory record Official record
Conditions
Injury
Interventions
Not listed
Lead sponsor
Poudre Valley Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Loveland, Colorado
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 2, 2026, 4:11 AM EDT
Recruiting Phase 2 Interventional

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

NCT06368817
View directory record Official record
Conditions
Basal Ganglia Germinoma, Diabetes Insipidus, Germinoma, Pineal Region Germinoma, Suprasellar Germinoma, Thalamic Germinoma
Interventions
3-Dimensional Conformal Proton Radiation Therapy, 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Carboplatin, Etoposide, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Lumbar Puncture, Magnetic Resonance Imaging, Questionnaire Administration, Surgical Procedure
Radiation · Procedure · Drug + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 29 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
97
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed No phase listed Observational Results available

I-Tracking Neurodegeneration in Early Wolfram Syndrome

NCT03951298
View directory record Official record
Conditions
Wolfram Syndrome
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Day and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Biological Basis of Individual Variation in Social Cooperation

NCT01566539
View directory record Official record
Conditions
Healthy
Interventions
Intranasal Oxytocin (OT) 24 IU, Intranasal Vasopressin (AVP), Intranasal Placebo, Intranasal Vasopressin (AVP) 40 IU, Lorazepam
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 30 Years
Enrollment
707 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 4 Interventional Results available

Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders

NCT02476409
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
tolvaptan, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy

NCT03064568
View directory record Official record
Conditions
Myomectomy; Surgical Blood Loss
Interventions
Misoprostol 200Mcg Tab, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
3
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 3 Interventional

"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia

NCT00072683
View directory record Official record
Conditions
Hyponatremias, Water Intoxication, Inappropriate ADH Syndrome, Water-Electrolyte Imbalances
Interventions
tolvaptan, placebo matching tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
23
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Recruiting Phase 2 Interventional

CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial

NCT05958342
View directory record Official record
Conditions
Trauma, Hemorrhage
Interventions
Calcium Gluconate, Vasopressin, saline placebo
Drug
Lead sponsor
Jason Sperry
Other
Eligibility
18 Years to 90 Years
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Chandler, Arizona • Tucson, Arizona • Little Rock, Arkansas + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Recruiting Phase 1 Interventional

Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency

NCT04789148
View directory record Official record
Conditions
Vasopressin Deficiency
Interventions
Intranasal Oxytocin (IN-OXT), Placebo
Drug
Lead sponsor
Elizabeth Austen Lawson
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed No phase listed Observational

Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery

NCT04369703
View directory record Official record
Conditions
Sellar and Suprasellar Masses, Pituitary Tumor
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 95 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Vasopressin on Glucose Regulation

NCT02761434
View directory record Official record
Conditions
Insulin Resistance
Interventions
Hypertonic Saline (3% NaCl), Isotonic Saline (0.9% NaCl)
Other
Lead sponsor
University of Arkansas, Fayetteville
Other
Eligibility
30 Years to 50 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 2, 2026, 4:11 AM EDT
Completed No phase listed Observational

Vasopressin Plasma Concentrations in Patients Receiving Exogenous Vasopressin Infusion for Septic Shock

NCT03014063
View directory record Official record
Conditions
Septic Shock
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 2, 2026, 4:11 AM EDT
Recruiting Phase 1 Interventional

A Study in Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus to Test the Effects of NDI-5001 Given for Multiple Days and to Test How NDI-5001 is Tolerated and Taken up in the Body

NCT07525960
View directory record Official record
Conditions
Diabetes Insipidus
Interventions
NDI-5001
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Active, not recruiting Phase 2 Interventional

AMX0035 in Adult Patients With Wolfram Syndrome

NCT05676034
View directory record Official record
Conditions
Wolfram Syndrome
Interventions
AMX0035
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
17 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Terminated Phase 1 Interventional

Metformin and Congenital Nephrogenic Diabetes Insipidus

NCT02460354
View directory record Official record
Conditions
Diabetes Insipidus
Interventions
Metformin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome

NCT02829268
View directory record Official record
Conditions
Wolfram Syndrome, Diabetes Mellitus, Optic Nerve Atrophy, Ataxia
Interventions
dantrolene sodium
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
5 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available

Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease

NCT01247090
View directory record Official record
Conditions
Hypertension, End Stage Renal Disease
Interventions
Vasopressin - Very Low Dose, Vasopressin - Low Dose, Placebo Comparator
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 4 Interventional

Vasopressin for Septic Shock Pragmatic Trial

NCT06217562
View directory record Official record
Conditions
Septic Shock
Interventions
Vasopressin, Recommendation to use a lower initiation threshold for vasopressin, Recommendation to use a higher initiation threshold for vasopressin
Drug · Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
3,959 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Burley, Idaho • American Fork, Utah • Cedar City, Utah + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Not applicable Interventional Results available

Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus

NCT00478335
View directory record Official record
Conditions
Nephrogenic Diabetes Insipidus
Interventions
sildenafil, calcitonin, hydrochlorothiazide/amiloride, indomethacin, Placebo for sildenafil, placebo for calcitonin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
5 Years to 25 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Vasopressin and the Social Brain

NCT02394054
View directory record Official record
Conditions
Social Psychology
Interventions
Intranasal vasopressin, Intranasal placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 30 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 2, 2026, 4:11 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Oxytocin and Arginine Vasopressin in Pain Relief

NCT01328561
View directory record Official record
Conditions
Placebo Analgesia
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Regulation of Arginine-vasopressin (AVP)

NCT02626832
View directory record Official record
Conditions
Schizophrenia, Depression
Interventions
Procedural
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 2, 2026, 4:11 AM EDT